Taren Grom, Editor
NOTE: The content below contains the first few paragraphs of the printed article and the titles of the sidebars and boxes, if applicable.
Letter from the Editor
Electronic Health Records Open Up New Opportunities
Talk of electronic medical records (EMR) and electronic health records (EHR) is a hot topic. These systems assist medical practitioners in the creation, storage, and organization of electronic medical records, including patient charts, electronic prescriptions, lab orders, evaluations, and patient communications, to name just a few common features. While the terms EMR and EHR are often used interchangeably, EMR solutions allow for patient information to be shared within one healthcare organization, whereas EHR solutions, which replace paper-based patient record systems, allow for health-related records to be shared across multiple organizations.
A recent CMI/Compas whitepaper reported that according to research by Medscape in 2012, 74% of physicians responded yes when asked if they are currently using an EHR system. The same study reports that the current EHR market is very fragmented, with most suppliers having less than 10% market share. It is predicted that there will be consolidation across the more than 300 EHR vendors; some will be acquired for list acquisition purposes while the high cost of business will lead to some smaller platforms going away.
EHR adoption is being driven by The Health Information Technology for Economic and Clinical Health (HITECH) Act of 2009, which provides financial incentives to be paid to providers who use EHRs in a substantial and meaningful way to manage patient care. This is referred to as Meaningful Use and is being rolled out in stages with each stage introducing stricter requirements for EHR adherence. By 2015, hospitals and doctors will be subject to financial penalties under Medicare if they are not using EHRs.
Experts and analysts alike agree that as the industry moves into Meaningful Use II, things will start to get interesting. There are additional requirements around patient access to and communication within EHR platforms. These include providing an InfoButton to patient education, secure communications, allowing patients to view their records, and providing reminders to patients.
CMI/Compas believes that increased engagement by the patient will improve efficiency, documentation, patient satisfaction, and adherence. Furthermore, they say this will lead to an increase in patient portals, which offer an opportunity for enhanced physician-patient communication.
This month’s Forum discusses the opportunities and challenges of EHR in the coming months and years. Some optimists in the industry believe that EHRs will provide pharma companies with another method for messaging physicians at the point of care, while skeptics believe pharma will have to take a back seat until all the evolving pieces of the Affordable Care Act are in place, and the healthcare industry in its entirety has mastered the function of EHRs.
In either scenario, there are opportunities for pharmaceutical companies and their partners to connect with patients, pardon the pun, in a much more meaningful way.
Denise Myshko, Managing Editor
Pharmaceutical companies are looking to big data tools and social media for better, faster trial recruitment.
Robin Robinson,Senior Editor
EHRs represent another channel to provide physician and patient education, but how the industry can effectively do that is still in question.
Kim Ribbink, Features Editor
Pharmaceutical companies are finding success in Malaysia thanks to growing government support, good infrastructure, and a trusted manufacturing environment.
Coming in June 2014
- Personalized Medicine
- Creating Great Creative
- DIA?Preview — 50th Anniversary
- Leadership Development: Board of Director Positions
- Advertising and Social Media
- C-Suite — Digital Marketing
- Market Focus — Thailand
- Showcase Feature — Clinical Trial Solutions
Volume 14 Number 5
Publisher – Lisa Banket
Editor – Taren Grom
Creative Director – Marah Walsh
Managing Editor – Denise Myshko
Senior – Editor Robin Robinson
Features Editor – Kim Ribbink
Design Associate – Ariel Medel
Director of Sales – Cathy Tracy
National Account Manager – Suzanne Besse
Webcast?Network?Producer – Daniel Limbach
Circulation Assistant – Kathy Deiuliis
by PharmaLinx LLC, Titusville, NJ
Printed in the U.S.A.
Volume Fourteen, Number Five
PharmaVOICE (ISSN: 1932961X) is published monthly except joint issues in July/Aug. and Nov./Dec., by PharmaLinx LLC, P.O.?Box 327, Titusville, NJ 08560. Periodicals postage paid at Titusville, NJ 08560 and additional mailing offices.
Postmaster: Send address changes to PharmaVOICE, P.O. Box 292345, Kettering, OH 45429-0345.
PharmaVOICE Coverage and Distribution:
Domestic subscriptions are available at $190 for one year (10 issues). Foreign subscriptions: 10 issues US$360. Contact PharmaVOICE at P.O.?Box 327, Titusville, NJ 08560. Call us at 609.730.0196 or FAX your order to 609.730.0197.
Contributions: PharmaVOICE is not responsible for unsolicited contributions of any type. Unless otherwise agreed in writing, PharmaVOICE retains all rights on material published in PharmaVOICE for a period of six months after publication and reprint rights after that period expires. E-mail: email@example.com.
Change of address: Please allow six weeks for a change of address. Send your new address along with your subscription label to PharmaVOICE, P.O. Box 292345, Kettering, OH 45429-0345. Call us at 800.607.4410 or FAX your change to 937.890.0221. E-mail: firstname.lastname@example.org.
Important notice: The post office will not forward copies of this magazine. PharmaVOICE is not responsible for replacing undelivered copies due to lack of or late notification of address change.
Advertising in PharmaVOICE: To advertise in PharmaVOICE please contact our Advertising Department at P.O.?Box 327, Titusville, NJ 08560, or telephone us at 609.730.0196. E-mail: email@example.com.
Send your letters to firstname.lastname@example.org. Please include your name, title, company, and business phone number. Letters chosen for publication may be edited for length and clarity. All submissions become the property of PharmaLinx LLC.